Subscribe

ALK Gene Rearrangement and PD-L1 Expression

Videos - Lung Cancer
Edward Garon, MD
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Related Items
Adjuvant Osimertinib a Practice-­Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on August 17, 2020 in Lung Cancer
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on August 17, 2020 in Lung Cancer
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue: Payers' Perspectives in Oncology published on August 17, 2020 in Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 19, 2020 in FDA Approvals, Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Web Exclusives published on June 8, 2020 in FDA Approvals, Lung Cancer
Last modified: April 27, 2017
Copyright © Engage Healthcare Communications, LLC. All rights reserved.